CONFERENCE PROCEEDING
Study on the toxicity of hemostatic materials based on sodium alginate
1
National Scientific Center for “Toxicological and Biological Safety of Medical Devices" Limited, Moscow, Russia
2
Department of Technology of Chemical, Pharmaceutical and Cosmetic Substances, D. Mendeleev University of Chemical Technology of Russia, Moscow, Russia
Publication date: 2026-07-30
Public Health Toxicol 2026;6(Supplement 1):A15
ABSTRACT
Introduction:
One of the most urgent issues in disaster medicine is providing first aid to stop bleeding. Finding new materials for hemostatic agents should focus not only on their effectiveness in stopping bleeding, but also on their toxicological safety. This paper presents a study on the toxicity for new hemostatic materials: sodium alginate, with and without aminocaproic acid added.
Methods:
The study of hemostatic materials involved the stages of sanitary and chemical testing, toxicological testing, and determination of hemostatic activity. Sanitary and chemical tests include the determination of pH changes, UV absorption, metal content, formaldehyde and volatile compounds in aqueous extracts.
Results:
All samples comply with the specified standards: there are no toxic metals (<0.001 mg/dm³), formaldehyde and residual organic solvents. The samples do not exhibit cytotoxicity (<10% cell death), sensitization, or irritant effects, and are apyrogenic. Hemostatic efficacy was tested, with the sample containing aminocaproic acid showing better results (70-78%) compared to pure alginate (6-30%).
Conclusion:
New hemostatic materials based on sodium alginate are safe and meet the requirements for biological and toxicological safety. The combination of alginate with aminocaproic acid significantly enhances the effectiveness of hemostasis. Further research into the use of these combined hemostatic agents in disaster medicine and surgery holds promise. Keywords. hemostatic materials, toxicity study of medical devices, sodium alginate, aminocaproic acid, assessment of hemostatic activity.
One of the most urgent issues in disaster medicine is providing first aid to stop bleeding. Finding new materials for hemostatic agents should focus not only on their effectiveness in stopping bleeding, but also on their toxicological safety. This paper presents a study on the toxicity for new hemostatic materials: sodium alginate, with and without aminocaproic acid added.
Methods:
The study of hemostatic materials involved the stages of sanitary and chemical testing, toxicological testing, and determination of hemostatic activity. Sanitary and chemical tests include the determination of pH changes, UV absorption, metal content, formaldehyde and volatile compounds in aqueous extracts.
Results:
All samples comply with the specified standards: there are no toxic metals (<0.001 mg/dm³), formaldehyde and residual organic solvents. The samples do not exhibit cytotoxicity (<10% cell death), sensitization, or irritant effects, and are apyrogenic. Hemostatic efficacy was tested, with the sample containing aminocaproic acid showing better results (70-78%) compared to pure alginate (6-30%).
Conclusion:
New hemostatic materials based on sodium alginate are safe and meet the requirements for biological and toxicological safety. The combination of alginate with aminocaproic acid significantly enhances the effectiveness of hemostasis. Further research into the use of these combined hemostatic agents in disaster medicine and surgery holds promise. Keywords. hemostatic materials, toxicity study of medical devices, sodium alginate, aminocaproic acid, assessment of hemostatic activity.
ACKNOWLEDGEMENTS
The study was carried out using the equipment of the National Scientific Center for “Toxicological and Biological Safety of Medical Devices" Limited, Moscow, Russia.
CONFLICTS OF INTEREST
The authors declare that they have no conflict of interests in the publication of this article. The authors have no conflicts of interest to report in this work. Abstract was not submitted elsewhere and was first published here.
FUNDING
This research received no external funding from any funding agency in the public, commercial, or not-for-profit sectors.
| eISSN: | 2732-8929 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
